U.S. court invalidates patent on Bristol hepatitis B drug

Tue Feb 12, 2013 9:54am EST

Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.

"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.